Association of genetic polymorphis of thymidylate synthase and methylene tetrahydro folate reductase with therapeutic effect of pemetrexed for treating advanced lung adenocarcinoma patients
10.3969/j.issn.1006-5725.2019.04.004
- VernacularTitle:晚期肺腺癌胸苷酸合成酶和亚甲基四氢叶酸还原酶基因多态性与培美曲塞化疗的临床效果
- Author:
Liyan BAI
1
;
Jun HAN
;
Dongmei WANG
;
Yujuan QI
Author Information
1. 青海省人民医院肿瘤内科
- Keywords:
advanced lung adenocarcinoma;
genetic polymorphis;
pemetrexed;
methylene tetrahydrofolate reductase;
thymidylate synthase
- From:
The Journal of Practical Medicine
2019;35(4):520-524
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expressions of thymidylate synthase (TS) and methylene tetrahydrofolate reductase (MTHFR) polymorphisms and the therapeutic efficacy of chemotherapy with pemetrexed and platinum in advanced lung adenocarcinoma patients. Methods Fifty-eight patients with advanced lung adenocarcinoma were enrolled in this study. The blood samples from 25 of them were examined for extraction of DNA. The associations of the gene polymorphisms with the chemotherapy efficacy and PFS were analyzed. Results Disease control rate was noted by 38％ and the median time of progression-free survival was 8.1 months among 58 patients.There were 16％, 32％, 52％, and TS genotypes as 2R/2R, 2R/3R and 3R/3R respectively; the difference in the control rate between those with TS gene of 3R/3R and those with TS gene of R/2R+2R/3 R was significant statistically (53.8％ vs. 91.7％, P = 0.046) , but the difference in PFS was statistically insignificant (9.3 vs. 10.4 months, P> 0.05). There were 40％, 52％, 8％, and MTHFR genotypes as CC, CT and TT respectively. The DCR in those with MTHFR CC and C/T + T/T was 70％ and 73.3％, respectively and PFS was 10 months and 9.7 months respectively, showing no significant difference (P> 0.05). Conclusion The TS gene polymorphism is associated with therapeutic effect of pemetrexed for advanced lung adenocarcinoma, but MTHFR is not.
